Logo

Seagen Entered into an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize Tivdak (tisotumab vedotin-tftv)

Share this

Seagen Entered into an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize Tivdak (tisotumab vedotin-tftv)

Shots:

  • Seagen to receive $30.0M up front, ~$78.0M upon achievement of development & regulatory milestones, ~$185.0M upon achievement of sales milestones along with royalties on annual net sales of licensed products in the licensed territory. Both companies will share 50:50 future costs and profits, based on Aug 2017 collaboration b/w Seagen & Genmab
  • Zai Lab gets an exclusive right to develop & commercialize the US FDA-approved Tivdak in Mainland China, Hong Kong, Macau & Taiwan
  • The collaboration will use Zai Lab’s expertise in developing & commercializing the therapies in the licensed territory. The collaboration also supports patient enrollment for the P-III (InnovaTV 301) trial of Tivdak in recurrent or metastatic cervical cancer

Ref: Businesswire | Image: Seagen

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions